Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
- Revenue in USD (TTM)15.00m
- Net income in USD-242.70m
- Incorporated2020
- Employees114.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | 0.00 | -155.20m | 3.15bn | 102.00 | -- | 5.60 | -- | -- | -2.37 | -2.37 | 0.00 | 9.15 | 0.00 | -- | -- | 0.00 | -22.39 | -53.19 | -24.37 | -59.03 | -- | -- | -- | -3,879.14 | -- | -- | 0.00 | -- | -- | -- | 25.39 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -512.54m | 3.18bn | 503.00 | -- | 3.08 | -- | -- | -2.97 | -2.97 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -40.69 | -25.08 | -44.21 | -29.47 | -- | -- | -- | -348.01 | -- | -- | 0.0055 | -- | -- | -- | -21.23 | -- | 25.15 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.30bn | 2.90k | -- | 3.26 | -- | 3.63 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.51bn | 233.00 | -- | 7.63 | -- | 158.63 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -345.91m | 3.64bn | 358.00 | -- | 6.02 | -- | 485.72 | -4.36 | -4.36 | 0.0946 | 7.27 | 0.0105 | -- | 5.28 | 20,949.72 | -48.34 | -27.62 | -51.10 | -28.67 | -- | -- | -4,612.13 | -2,733.56 | -- | -- | 0.00 | -- | -- | -25.26 | -47.62 | -- | -21.24 | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.69bn | 53.00 | -- | 5.74 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 3.81bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| Centessa Pharmaceuticals PLC - ADR | 15.00m | -242.70m | 3.83bn | 114.00 | -- | 11.68 | -- | 255.10 | -1.82 | -1.82 | 0.1126 | 2.24 | 0.0284 | -- | 0.3252 | 194,805.20 | -45.88 | -57.03 | -48.42 | -62.05 | -- | -- | -1,617.99 | -14,516.02 | -- | -- | 0.2669 | -- | -100.00 | -- | -56.04 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.84bn | 796.00 | 9.87 | 3.12 | 9.52 | 3.58 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 3.93bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.20bn | 594.00 | -- | 3.87 | -- | 545.84 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.37bn | 103.00 | -- | 11.50 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.41bn | 59.00 | -- | 12.79 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -141.20m | 4.47bn | 220.00 | -- | 2.94 | -- | -- | -2.49 | -2.49 | 0.00 | 21.41 | 0.00 | -- | -- | 0.00 | -11.35 | -18.40 | -11.83 | -19.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.24 | -- | 185.66 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.50bn | 511.00 | -- | 16.25 | -- | 7.10 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
Data as of Mar 03 2026. Currency figures normalised to Centessa Pharmaceuticals PLC's reporting currency: US Dollar USD
43.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 14.56m | 10.89% |
| Adage Capital Management LPas of 31 Dec 2025 | 11.28m | 8.44% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 8.06m | 6.03% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 5.38m | 4.02% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 3.96m | 2.97% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 3.93m | 2.94% |
| EcoR1 Capital, LLCas of 31 Dec 2025 | 3.12m | 2.33% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 2.92m | 2.18% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 2.37m | 1.77% |
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 2.34m | 1.75% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
